1. 5-year progression-free survival was increased in the induction chemotherapy group compared to standard chemoradiotherapy. 2. Patients in the induction ...
Click to read this study in Clinical Cancer Research.
Click to read this study in the Journal of Clinical Oncology.
1. The failure-free-survival at 3 years for induction chemotherapy with paclitaxel, cisplatin and capecitabine group was 83.5% versus 68.9% in ...
Click to read this study in JAMA Oncology.
Click to read the study in Nature Communications.
Click to read the study in The Lancet Oncology.
